Literature DB >> 19921106

[Primary cutaneous CD30+ ALK(-) anaplastic large cell T-cell lymphoma].

C Mühlhoff1, A Rübben, N Gassler, M Megahed.   

Abstract

Anaplastic large cell lymphomas (ALCL) are characterized by large, pleomorphic cells with a strong expression of cytokine receptor CD 30. We present a 71-year-old patient with several nodules on the right temple extending to his right ear. Based on clinical, histological and immunophenotypic criteria, the diagnosis of a primary cutaneous CD30(+) ALK(-) anaplastic large cell lymphoma was made. After local excision and adjuvant radiotherapy no relapse occurred during a follow-up period of three months.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19921106     DOI： 10.1007/s00105-009-1874-2

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  13 in total

Review 1.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma').

Authors:  R Rimokh; J P Magaud; F Berger; J Samarut; B Coiffier; D Germain; D Y Mason
Journal:  Br J Haematol       Date:  1989-01       Impact factor: 6.998

3.  Variable expression of leucocyte-common (CD45) antigen in CD30 (Ki1)-positive anaplastic large-cell lymphoma: implications for the differential diagnosis between lymphoid and nonlymphoid malignancies.

Authors:  B Falini; S Pileri; H Stein; D Dieneman; F Dallenbach; G Delsol; O Minelli; S Poggi; M F Martelli; G Pallesen
Journal:  Hum Pathol       Date:  1990-06       Impact factor: 3.466

4.  Ki-1-positive large cell lymphoma. A clinicopathologic study of 41 cases.

Authors:  A Chott; K Kaserer; I Augustin; M Vesely; R Heinz; W Oehlinger; H Hanak; T Radaszkiewicz
Journal:  Am J Surg Pathol       Date:  1990-05       Impact factor: 6.394

Review 5.  The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants.

Authors:  D N Slater
Journal:  Br J Dermatol       Date:  2005-11       Impact factor: 9.302

6.  CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group.

Authors:  M Paulli; E Berti; R Rosso; E Boveri; S Kindl; C Klersy; M Lazzarino; G Borroni; F Menestrina; M Santucci
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

7.  Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype.

Authors:  P C de Bruin; R C Beljaards; P van Heerde; P Van Der Valk; L A Noorduyn; J H Van Krieken; J C Kluin-Nelemans; R Willemze; C J Meijer
Journal:  Histopathology       Date:  1993-08       Impact factor: 5.087

8.  Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations.

Authors:  M Beylot-Barry; A Groppi; B Vergier; K Pulford; J P Merlio
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

9.  Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity.

Authors:  M Shiota; S Nakamura; R Ichinohasama; M Abe; T Akagi; M Takeshita; N Mori; J Fujimoto; J Miyauchi; A Mikata; K Nanba; T Takami; H Yamabe; Y Takano; T Izumo; T Nagatani; N Mohri; K Nasu; H Satoh; H Katano; J Fujimoto; T Yamamoto; S Mori
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

10.  Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population.

Authors:  H Stein; J Gerdes; U Schwab; H Lemke; D Y Mason; A Ziegler; W Schienle; V Diehl
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.